Arachidonic acid is an essential unsaturated fatty acid and is the most abundant in cell membranes. Its metabolism leads to the formation of the well known prostaglandins and thromboxanes, which are implicated in the modulation of vascular tone and growth and play an important role on the blood-vessel interface. The discovery of their pharmacological activity led to the development of some potent drugs such as the prostacyclin analogues, while thromboxane A 2 -receptor antagonists are currently under development. While research on arachidonic acid metabolites focused for decades on the enzymatic pathway, Morrow and Roberts 1 described in 1990 another pathway of arachidonic acid metabolism, i.e., a free radical pathway, leading to a large series of compounds termed isoprostanes.
A first level of complexity is that, unlike the enzymatic formation of prostaglandins, F 2 -isoprostanes derive from a non-specific free radical attack of arachidonic acid, i.e., that four different series of compounds, called regioisomers, differing in the nature of their side chains, are formed (Fig. 1) . The second level of complexity is that eight isomers may be formed among each of these four regioisomers, i.e., 64 different F 2 -isoprostanes are formed. The third level of complexity is man-made: three different nomenclatures co-exist 2 . Given the potential number of compounds, this can lead to a nightmare for the non-specialist, and a puzzle for novices to determine which is which. For clarity, the nomenclature validated by the International Union of Pure and Applied Chemistry 3 should be used. The fourth level of complexity is that F 2 -isoprostanes are only one family of the myriad of compounds produced through free radical peroxidation of arachidonic acid, including two recent families of compounds termed isoketals and isofurans ( Fig. 1) 4 . Most currently available data concerns the isoprostanes from the 15-series, especially 15-F 2t -IsoP (formerly named 8-iso-PGF 2 ). 15-F 2t -IsoP is a vasoconstrictor in most species and vascular beds 5 . These constrictor properties are not restricted to blood vessels, and have been demonstrated in the lymphatic vessels, the bronchi, the gastrointestinal tract and the uterus. In addition, 15-F 2t -IsoP stimulates mitogenesis 6 , enhances monocytes and polymorphonuclear adhesion to endothelial cells 7 , and induces endothelial cell necrosis 8 . While most of these effects are mediated by thromboxane A 2 -prostaglandin H 2 (TP) receptor stimulation, other effects such as PPAR activation 9 is TP receptor independent. However, there is no evidence to date that a specific isoprostane receptor exists. Acting as a partial agonist, 15-F 2t -IsoP inhibits platelet aggregation in human whole blood 10 . 15-F 2t -IsoP is released in conditions associated with free radical generation, such as cardiac ischaemia-reperfusion, and is the most sensitive and specific biomarker of lipid peroxidation in vascular disorders 11 . Several authors have tried to answer an important question: are these compounds merely biomarkers, or do they act as mediators in pathological conditions 12, 13 ? As we do not possess a pharmacological agent that may specifically inhibit the biological effects of 15-F 2t -IsoP, the answer cannot be straightforward. concentrations might be sufficiently high to induce regional vasoconstriction. Indeed, the concentrations of 15-F 2t -IsoP and 5-F 2t -IsoP were increased markedly (from basal levels) in the coronary sinus and plasma following coronary angioplasty 14, 15 . 15-F 2t -IsoP concentrations were in the nanomolar range, and thus unlikely to contribute to epicardial coronary artery vasoconstriction 16 . However, the concentration of 15-F 2t -IsoP might be sufficiently high to induce a vasoconstriction in the microcirculation because the potency of 15-F 2t -IsoP seems to be higher in these arteries compared with conductance arteries 17 . Considering 5-F 2t -IsoP, this compound does not possess any vasomotor activity 18, 19 , and is therefore unlikely to play a pathogenic role on the coronary vasculature.
No specific inhibition of 15-F 2t -IsoP or other isoprostane vascular effects can currently be achieved. However, TP receptor antagonists but not aspirin, are effective in the inhibition of atherosclerosis in apo E-KO (knock-out) mice, showing that TP receptor blockade by S18886 is effective by a mechanism independent of platelet-derived thromboxane A 2 20 , whereas isoprostane suppression with vitamin E retards atherogenesis in the same animal model 21 . Similarly, TP receptor antagonism by L670596, but not COX-2 inhibition, prevented pulmonary hypertension and endothelin-1 upregulation in 60% O 2 -mediated pulmonary hypertension in newborns rats 22 . In addition to these animal data, a study showed that in patients suffering from coronary artery disease, S18886 (a TP receptor antagonist) improved acetylcholine-induced and flow-mediated vasodilation in patients treated with aspirin 23 . An hypothesis is that endogenous TP receptor activation induced by 15-F 2t -IsoP or other isoprostanes may be involved in the COX-independent effects of TP receptor antagonists 24 . However, because TP receptors share other endogenous ligands such as prostaglandin H 2 or HETEs, such data give strength to the hypothesis that isoprostanes are involved in the vascular physiology and pathogenesis, but does not enable a definitive conclusion.
Given that many isomeric isoprostanes exist, one should not focus only on 15-F 2t -IsoP. Other isoprostanes possess potent pharmacological activity, the most potent ones being the isoprostanes from the E series. For example, 15-E 2t -IsoP is 10 times more potent than 15-F 2t -IsoP in systemic as well as pulmonary vessels 25, 26 . Furthermore, in a recent report Hou et al., 19 showed that many other regioisomers, including those from the 12-series, constricted retinal and brain microvessels. These regioisomers are likely to be produced under the same conditions as 15-F 2t -IsoP, but no data is currently available concerning their production in cardiac ischaemia-perfusion. Finally, other potential physiological mediators of the isoprostane pathway include the isothromboxanes 27 and the receptor independent effects of isoketals, that rapidly adduct to membrane proteins 28 . Isoprostanes are currently the more valuable biomarkers of lipid peroxidation 11 . They have been measured in Fig. 1 The isoprostane pathway.
biological fluids such as urine, plasma, exhaled breath condensate, bronchoalveolar lavage fluid, bile, cerebrospinal, seminal and pericardial fluids. They were also detectable in normal tissues, including umbilical cords 29 . Their measurement in biological fluids has prompted clinical investigations on the pathophysiological role of lipid peroxidation in cardiovascular diseases (see 30, 31 ). Among the biological fluids available, most studies were performed on urine because of the non-invasiveness of the procedure and the lack of artefactual generation. A strong link between lipid peroxidation and vascular diseases associated with ischaemia-reperfusion, atherosclerosis and inflammation has been suggested by the elevated levels of lipid peroxidation observed in such diseases.
In addition to being a pathophysiological marker, the quantification of F 2 -isoprostanes might represent a prognostic marker. F 2 -isoprostane levels consistently correlate to the severity of heart failure 32, 33, 34 , and correlate to the haemodynamic response to NO in pulmonary hypertension 35 . Furthermore, Schwedhelm et al., showed in a recent case-control study that urinary 15-F 2t -IsoP was a strong independent concentration-dependent risk marker of coronary heart disease 36 . There are currently no published clinical studies aimed at testing isoprostanes as a long-term prognostic marker, with strong endpoints such as mortality or morbidity, but at least two cohort studies are currently on-going.
In conclusion, we are just beginning to explore the wilderness of arachidonic acid metabolism leading to isoprostane formation. While the available data provides fuel for discussion concerning the potential implication of 15-F 2t -IsoP in vascular disorders, the unknown physiological and pathological significance of the myriad of compounds produced from arachidonic acid in conditions of enhanced free radical generation, observed in many vascular diseases, leaves scope for many more investigations.
